Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its current reports, financial updates, and material event announcements. These documents offer detailed insight into how Crinetics manages its endocrine-focused pharmaceutical business, including product approvals, clinical milestones, financing activities, and governance matters.
Crinetics uses Form 8-K to report significant events. Recent 8-K filings have addressed topics such as U.S. FDA approval of PALSONIFY™ (paltusotine) for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, research and development updates tied to major medical meetings, and financial results for specific reporting periods. Other 8-Ks describe executive transitions, including changes in senior medical leadership and related transition and advisory agreements, with details on severance, advisory compensation, and equity award treatment.
Crinetics also files 8-Ks in connection with its capital markets activity, such as underwritten public offerings of common stock under an automatically effective shelf registration statement. These filings typically outline the size of the offering, use of proceeds—such as funding commercialization of PALSONIFY, research and development of product candidates, and general corporate purposes—and the involvement of underwriters.
In addition to 8-Ks, investors can expect to find annual reports on Form 10-K and quarterly reports on Form 10-Q in the broader SEC record, which provide more comprehensive discussions of Crinetics’ endocrine and endocrine-related tumor programs, risk factors, and financial statements. Form 4 filings, when present, disclose insider transactions in CRNX equity, offering visibility into trading by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify information about product approvals, clinical trial progress for candidates such as atumelnant and CRN09682, equity offerings, and leadership changes. Real-time updates from EDGAR, combined with simplified explanations of complex sections in 10-K and 10-Q reports, make this page a practical resource for reviewing Crinetics’ regulatory history and ongoing disclosure obligations.
CRNX filing reports proposed and recent sales of Common Stock by an affiliated holder. The filing lists an exercise of stock options for 20,900 shares on 04/14/2026 (cash exercise) and multiple 10b5-1 sales executed by Jeff Knight: 9,911 shares on 03/16/2026, 85,163 shares on 04/08/2026, and 4,434 shares on 04/13/2026, with cash proceeds shown per trade.
Morgan Stanley Smith Barney LLC reported a Form 144 notice for sale of 4,434 shares of Common Stock of CRNX tied to exercise of stock options on 04/13/2026. The filing also lists prior 10b5-1 sales by Jeff Knight: 85,163 shares on 04/08/2026 and 9,911 shares on 03/16/2026, with proceeds shown in the filing.
Crinetics Pharmaceuticals Chief Dev. & Operating Officer Jeff E. Knight reported an exercise-and-sale transaction in company stock. On April 8, 2026, he exercised stock options to acquire a total of 78,434 shares of Common Stock at exercise prices of $23.98, $20.02, and $19.64 per share.
On the same date, Knight sold 85,163 shares of Common Stock in open market transactions at a volume weighted average price of $40.10 per share, with individual sale prices ranging from $40.00 to $40.34. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 105,289 shares of Crinetics common stock.
Crinetics Pharmaceuticals, Inc. reports that Jeff Knight’s previously disclosed resignation as Chief Development and Operating Officer became effective on April 10, 2026. On that date, the company and Mr. Knight entered into an Independent Consultant Agreement covering operational and clinical development services.
The consulting term runs from April 10, 2026 to April 10, 2027, with an option to renew for six months if both sides agree in writing. Mr. Knight will be paid $400 per hour, up to 20 hours per month, plus reimbursement of reasonable pre-approved expenses. His unvested restricted stock units and stock options are forfeited on the resignation date, while vested options remain exercisable for three months after the consulting period ends or earlier termination for cause. He also provides a general release of claims, and the company extends certain indemnification rights during the consulting term.
CRNX files a Form 144 disclosing proposed resale transactions of its Common Stock. The notice lists a reported sale of $370,411.47 for 9,911 shares on 03/16/2026. The filing also itemizes securities related to exercise of stock options (78,434 shares, 04/08/2026), an Employee Stock Purchase Plan entry (438 shares, 05/20/2025), and Restricted Stock Units (6,291 shares, 03/15/2024).
The Form 144 is a notice of proposed sale by an affiliate and describes the method of sale as cash transactions. It reports the broker/dealer and issuer entries tied to each lot; the filing does not state additional proceeds disposition or timing beyond the listed dates.
Crinetics Pharmaceuticals receives an amended Schedule 13G from The Vanguard Group reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries report holdings separately.
The filing is signed March 26, 2026 by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's Malvern, Pennsylvania address and Crinetics' principal executive office in San Diego.
Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices.
Crinetics plans to reassign all of Mr. Knight’s managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time.
Crinetics Pharmaceuticals Chief Operating Officer Jeff E. Knight sold 9,911 shares of common stock in open-market transactions. The sales on March 16, 2026 were executed at volume-weighted average prices of $37.11 and $37.77 per share.
According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of previously granted restricted stock units and were carried out by a broker under a Rule 10b5-1 trading plan. After the transactions, Knight directly holds 112,018 shares of Crinetics common stock.
Crinetics Pharmaceuticals Chief Scientific Officer Stephen F. Betz reported selling a total of 10,612 shares of common stock on March 16, 2026 in open-market transactions. One block of 6,371 shares was sold at a volume-weighted average price of $37.11 per share, and another 4,241 shares at $37.77 per share.
According to the footnotes, these sales were made to cover his tax withholding obligations upon the vesting of previously granted restricted stock units and were executed by a broker under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Betz directly holds 137,101 shares of Crinetics common stock.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported tax-related share sales. On March 16, 2026, he sold a total of 21,981 shares of common stock in open-market transactions, including 13,196 shares at a volume-weighted average price of $37.11 and 8,785 shares at $37.77.
According to the disclosure, these shares were sold by a broker to cover the CEO's tax withholding obligations upon the vesting of restricted stock units granted on February 28, 2022, March 1, 2023, and March 4, 2024, under a Rule 10b5-1 trading plan. After the sales, he directly holds 404,778 shares of common stock and has additional indirect holdings through several family trusts and his spouse.